Financial Performance - Revenue decreased by 13.5% to approximately RMB 917,341,000 (2024: RMB 1,061,082,000) [3] - Gross profit decreased by 8.3% to approximately RMB 247,905,000 (2024: RMB 270,446,000) [3] - Profit before tax decreased by 39.9% to approximately RMB 57,433,000 (2024: RMB 95,519,000) [3] - Net profit decreased by 47.8% to approximately RMB 38,892,000 (2024: RMB 74,466,000) [3] - Profit attributable to owners of the company decreased by 72.9% to approximately RMB 11,282,000 (2024: RMB 41,557,000) [3] - Basic earnings per share decreased by 73.4% to approximately RMB 1.92 (2024: RMB 7.22) [3] - Total comprehensive income for the year was RMB 22,335,000, down from RMB 74,639,000 in 2024 [5] Revenue Breakdown - Revenue from pharmaceutical products for 2025 is RMB 603,762,000, a decrease of 19.5% from RMB 749,692,000 in 2024 [16] - Revenue from healthcare products for 2025 is RMB 54,440,000, down 13.5% from RMB 62,981,000 in 2024 [16] - Total revenue for 2025 is RMB 917,341,000, a decline of 13.5% compared to RMB 1,061,082,000 in 2024 [16] - OTC and agency business saw a revenue of RMB 759.49 million in 2025, a year-on-year decline of 18.1% [43] - Hong Kong business recorded a revenue of RMB 8.534 million, a slight decrease of 2.1% year-on-year, while the Hong Kong Fozi segment achieved a revenue of RMB 11.359 million, growing by 55.5% year-on-year [43] - E-commerce business generated sales of RMB 12.29 million in 2025, down 46.5% year-on-year due to rising traffic costs and intensified platform competition [44] - The medical services segment recorded a revenue of RMB 2.01 million in 2025, reflecting a significant growth of 357.9% year-on-year [44] Cost and Expenses - The cost of sales was approximately RMB 669,436,000, a decrease of about RMB 121,200,000 or 15.3%, with gross profit of approximately RMB 247,905,000, down RMB 22,541,000 or 8.3% [88] - The group's administrative expenses increased by approximately RMB 8,497,000 or 9.4% to about RMB 99,154,000, mainly due to higher depreciation and intermediary fees [91] - Employee costs for 2025 amount to RMB 120,861,000, a decrease of 9.0% from RMB 132,850,000 in 2024 [19] Cash Flow and Financial Position - Cash and cash equivalents increased to RMB 264,410,000 from RMB 235,299,000 in 2024 [7] - As of December 31, 2025, the group had cash and cash equivalents of approximately RMB 264,410,000, an increase from RMB 235,299,000 as of December 31, 2024, primarily driven by operating income [106] - The total bank borrowings due within one year as of December 31, 2025, were approximately RMB 265,006,000, up from RMB 225,664,000 as of December 31, 2024 [102] - The capital debt ratio as of December 31, 2025, was approximately 21.8%, slightly up from 21.6% as of December 31, 2024, mainly due to a decrease in total equity [103] Dividends and Shareholder Returns - The board resolved not to recommend any final dividend for the year ended December 31, 2025 (2024: HKD 0.0317 per share) [3] - The company did not declare any final dividends for the year ending December 31, 2025, compared to a dividend of HKD 0.0317 per share in 2024 [27] Market Trends and Strategic Focus - The OTC industry in China is projected to exceed RMB 350 billion during the 14th Five-Year Plan period, with a compound annual growth rate of approximately 6% [33] - The company anticipates that the demand for healthcare products will continue to grow, driven by increasing health awareness and spending among consumers [29] - The company is focusing on enhancing supply chain resilience and flexibility in response to external pressures, including geopolitical factors and inflation [30] - The digital transformation in retail pharmacy is expected to elevate the role of pharmacies to health data interaction and professional consultation hubs, requiring improved organizational agility [34] Product Development and Innovation - The company is actively developing new products targeting women's and men's health, leveraging the unique opportunities presented by the Greater Bay Area policy [40] - The approval of 14 new traditional Chinese medicine products by the National Medical Products Administration in the first half of 2025 indicates a growing market for innovative TCM [39] - The group has launched a patented dual-brand product, "Corydalis Oral Liquid," targeting the constipation market, particularly for the elderly, with expected significant sales growth due to increasing market demand [50] - The "Jianfu Capsule," a patented product for women's reproductive health, has shown clinical value in improving hormone levels and is expanding into grassroots markets, supported by rising infertility rates and government policies [50] Corporate Governance and Compliance - The board is committed to adhering to the corporate governance code and has implemented measures to enhance internal control systems [134] - The company has adopted the standard code of conduct for securities trading as per the listing rules, confirming that all directors complied with the code during the review period [136] - The Audit Committee confirmed that the accounting policies and practices adopted by the group comply with current accounting standards and listing rules [138] Community Engagement and Corporate Social Responsibility - The company has donated nearly RMB 3 million worth of health capsules to grassroots medical networks in Guangdong, Hunan, and Jiangxi, focusing on women's health and welfare [73] - The company has donated RMB 300,000 for disaster relief efforts and provided essential supplies to affected areas, demonstrating its commitment to corporate social responsibility [72] Future Outlook and Strategic Initiatives - The company plans to officially launch its "AI Digital Platform" by 2026, focusing on marketing forecasting, user profiling, and personalized product information services to enhance decision-making and market expansion [115] - The group aims to enhance its global development momentum by deepening the layout of the global health industry value chain in line with national policy directions [113] - The group plans to optimize talent structure and incentive mechanisms to strengthen professional and youthful team building, enhancing organizational execution and innovation [69]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 股東及潛在投資者在買賣本公司股份時，務請審慎行事。 承董事會命 本公告乃金活醫藥集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 證券及期貨條例（香港法例第571章）第XIVA部之內幕消息條文及香港聯合交易所 有限公司證券上市規則第13.09(2)條而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資 者，基於本集團截至二零二五年十二月三十一日止年度（「本年度」）之未經審核綜 合管理賬目及董事會目前可得的資料之初步評估，本集團預期二零二五年下半年 之本公司擁有人應佔溢利，已從上半年的虧損約人民幣5.4百萬元，轉虧為盈，錄 得溢利。但本集團仍然預期本年度之本公司擁有人應佔溢利將較截至二零二四年 十二月三十一日止年度（「上年度」）的人民幣41.6百萬元減少約70%至75%。 董事會認為本公司擁有人應佔溢利減少主要是由於以下因素： 1 (i) 由於從事品牌進口醫 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 董事會會議通告 金活醫藥集團有限公司（「本公司」，及其附屬公司，統稱「本集團」）之董事（「董 事」）會（「董事會」）茲通告，謹定於二零二六年三月三十一日星期二於香港九龍荔 枝角道808號好運工業中心6樓613室會議室舉行董事會會議，目的為審議並批准 本集團截至二零二五年十二月三十一日止年度的經審計年度業績及建議派付末期 股息（如有），並處理任何其他事項。 承董事會命 金活醫藥集團有限公司 主席 趙利生 香港，二零二六年三月十八日 於本通告日期，執行董事為趙利生先生、陳樂燊女士及周旭華先生；獨立非執行董事為段繼東 先生、黃焯琳先生及儲小平博士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01110 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 FF ...

公司名稱: 金活醫藥集團有限公司 呈交日期: 2026年2月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01110 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.1 | HKD | | 1,000,000,000 | 本月 ...

Group 1 - The core point of the announcement is that King活医药 Group plans to acquire a well-known pharmaceutical company in Hong Kong for a cash consideration of HKD 66.4368 million, which will enhance its market presence and leverage the target company's brand influence for further expansion [1][2] - The acquisition price consists of HKD 41.5 million for the target company's core business and production equipment, and HKD 24.9368 million for real estate assets [1] - The chairman of King活医药 emphasized that this acquisition is a key move to enhance the health industry chain and global strategy, aligning with the company's extensive distribution network across 34 provinces and regions [2][3] Group 2 - The memorandum stipulates that King活医药 will pay a deposit of HKD 3.32184 million within five working days, which does not constitute a significant transaction under Hong Kong Stock Exchange rules [2] - Industry analysts believe that this acquisition will enrich the company's brand portfolio and strengthen its market position in Hong Kong and Macau, while also facilitating broader international market outreach [3] - The acquisition is seen as a strategic move to fill gaps in the company's pharmaceutical manufacturing capabilities and support its long-term goal of becoming a globally influential health industry platform [3]

Core Viewpoint - Kingworld Medicines Group (01110) has entered into a memorandum of understanding regarding a proposed acquisition, which is expected to be paid in cash [1] Group 1: Acquisition Details - The total consideration for the acquisition includes a base purchase price of HKD 66.4368 million, which consists of HKD 41.5 million related to the target company's business and production equipment (excluding vehicles) and HKD 24.9368 million related to real estate properties [1] - The acquisition price will also include the net book value of the target company's equipment (excluding any vehicles) at completion and the net working capital at completion, which is defined as the total of accounts receivable and inventory minus accounts payable, subject to adjustments based on audited accounts prepared in accordance with Hong Kong Financial Reporting Standards [1] - A deposit of approximately HKD 3.3218 million will be paid to the proposed seller within five business days from the signing of the memorandum of understanding [1] Group 2: Strategic Implications - The target company is registered in Hong Kong and primarily engaged in the production and sale of pharmaceuticals, operating within real estate properties [1] - The board believes that if the proposed acquisition is realized, it will enable the group to expand its footprint in the Hong Kong pharmaceutical industry, acquire valuable manufacturing assets including real estate properties, and promote the group's domestic and international business development through synergies in product distribution and operational scale [1]

Core Viewpoint - King活医药集团 (01110) has announced a proposed acquisition involving its wholly-owned subsidiary, King活医药 (BVI), which is expected to be paid in cash [1] Group 1: Acquisition Details - The total consideration for the acquisition includes a base purchase price of HKD 66.4368 million, comprising HKD 41.5 million for the target company's related business and production equipment (excluding vehicles) and HKD 24.9368 million for real estate properties [1] - The consideration will also include the net book value of the target company's equipment (excluding any vehicles) at completion and the net working capital at completion, which is defined as the total of accounts receivable and inventory minus accounts payable, subject to adjustments based on audited accounts prepared in accordance with Hong Kong Financial Reporting Standards [1] - A deposit of approximately HKD 3.3218 million will be paid to the proposed seller within five business days from the signing of the memorandum of understanding [1] Group 2: Strategic Implications - The target company is registered in Hong Kong and primarily engaged in the production and sale of pharmaceuticals, operating within real estate properties [1] - The board believes that if the proposed acquisition is realized, it will enable the group to expand its footprint in the Hong Kong pharmaceutical industry, acquire valuable manufacturing assets including real estate properties, and promote the group's domestic and international business development through synergies in product distribution and operational scale [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 自願公告 有關建議收購事項之諒解備忘錄 本公告由金活醫藥集團有限公司自願作出。 董事會欣然宣佈，於二零二六年一月二十二日（交易時段後），本公司之全資附 屬公司金活醫藥(BVI)就建議收購事項與擬定賣方及擔保人訂立諒解備忘錄。目 標公司主要從事藥品生產及銷售並持有地產物業。預計代價將以現金支付。擔 保人同意就擬定賣方履行其於諒解備忘錄項下之責任提供擔保。 自簽訂諒解備忘錄起五個營業日內，金活醫藥(BVI)將向擬定賣方支付按金 3,321,840港元。由於就支付按金而言，上市規則項下之相關百分比率均低於 5%，故訂立諒解備忘錄並不構成上市規則第十四章項下本公司之須予公佈交 易。 倘建議收購事項得以落實，則可能構成上市規則第十四章項下本公司之須予披 露交易。 董事會謹此強調，於本公告日期，金活醫藥(BVI)並未就建議收購事項與任何人 士訂立具法律約束力之協議（諒解備忘錄內有關（其中包括）按金、盡職審查、 排他 ...

Core Insights - The article highlights the successful integration of modern agriculture and global supply chains, particularly focusing on the winter availability of strawberries from Dandong, China, and cherries (referred to as "车厘子") from Chile, which cater to the Chinese New Year market demand [1][2][3] Group 1: Seasonal Availability - Strawberries, traditionally a spring fruit, are now available year-round due to advanced cultivation techniques, with Dandong farmers harvesting multiple crops from August to March [2][3] - Chilean cherries are harvested from November to February, coinciding with the winter season in the Northern Hemisphere, allowing for a continuous supply of fresh cherries during the Chinese New Year [3] Group 2: Preservation Techniques - Dandong strawberries maintain freshness through rapid cooling and cold chain logistics, with a two-hour window for pre-cooling after harvest, ensuring delivery within 48 hours [4] - Chilean cherries utilize a combination of quick cooling and modified atmosphere packaging to extend shelf life, with cherries entering ice water within 3-4 hours post-harvest [4] Group 3: Food Safety Measures - Dandong strawberries are cultivated using green farming techniques, including organic fertilizers and physical pest control, ensuring a safe product for consumers [5] - Chilean cherries adhere to strict export standards, with quality checks at both the source and upon arrival in China, providing a dual layer of safety for consumers [6] Group 4: Financial Support for Agriculture - Guangfa Bank has introduced innovative financial products to support the strawberry and cherry industries, including a specialized loan program for strawberry farmers in Dandong, with a maximum credit limit of 300,000 yuan [7] - The bank's services extend to the logistics and sales chain for Chilean cherries, facilitating timely financing for international procurement and domestic logistics [7] Group 5: Conclusion - The article emphasizes the collaborative efforts of farmers, technology, and financial institutions in ensuring the availability of fresh strawberries and cherries, showcasing a model of modern agricultural practices [8]